Maplight Therapeutics, Inc. (MPLT)
AI stock analysis · as of Jul 28, 2026
Loading microstructure…
MapLight Therapeutics (MPLT) is a clinical-stage CNS biotech that IPO'd in October 2025 with a lead M1/M4 muscarinic agonist (ML-007C-MA) positioned as a better-tolerated challenger to Bristol Myers Squibb's approved Cobenfy in schizophrenia, plus pipeline shots in ASD, Parkinson's and Alzheimer's disease psychosis. The core investment question has been dramatically reframed: after a July 27, 2026 Phase 2 ZEPHYR readout in which the commercially critical once-daily dosing arm missed, is the stock at ~$9.90 (down from a $40 high) mispriced given some surviving efficacy signals, remaining pipeline optionality (IRIS/ASD, ADP, PD), and $46.7M cash, or is it a value trap facing dilution and a broken lead-asset narrative?
valuationOptically cheap at 1.12x P/B and near cash-adjusted enterprise value, but this is standard for a post-blowup pre-revenue biotech — valuation is a function of pipeline probability-weighted NPV, not multiples, and the market is signaling deep skepticism about ML-007's commercial viability.
This analysis is from Jul 28, 2026. Want the latest on MPLT, plus the ability to generate fresh research on demand?
Every call we make is tracked publicly against what the stock actually did. See the track record →
One free AI report every day. No card required.
Bull case
- · Stock has already collapsed ~73% from 52-week high to $9.90, trading at just 1.12x price-to-book with market cap of $449M — much of the once-daily failure appears priced in
- · Trial reportedly hit a key Phase 2 goal despite the once-daily miss, and TD Cowen, BMO, and Jefferies maintained positive ratings, suggesting a twice-daily commercial path may remain viable
- · IRIS Phase 2 readout in ASD remains a live, independent catalyst — ASD has no approved core-symptom therapy, offering optionality not impaired by the ZEPHYR miss
- · Analyst consensus target of $43.85 (13 analysts, strong_buy) implies >340% upside if even a fraction of the pre-readout thesis is restored
- · Insiders hold 51.6% and institutions 57%, indicating meaningful skin-in-the-game alignment; insider_net_sells_180d is $0 (no net selling)
- · Retained global rights across all programs preserves partnership/licensing optionality; management guides cash runway into 2027 covering remaining catalysts
Bear case
- · Lead asset's key commercial differentiator (once-daily dosing vs. Cobenfy) failed in Phase 2 ZEPHYR — the primary reason for the drug's existence is now in question
- · Morgan Stanley downgraded and Wolfe cut its price target post-readout, signaling institutional loss of confidence on the lead program
- · Only $46.7M cash against a $138.6M annual FCF burn — runway math is tighter than management framing suggests, and further dilutive raises are near-certain
- · ROE of -81% and net loss of $161M in 2025 with zero revenue; company is entirely capital-markets dependent, and its post-crash equity is a much more expensive currency to raise against
- · Direct competition from BMS's already-approved Cobenfy (with Phase 3 programs across multiple indications) and other M4-selective agonists — MapLight's tolerability edge remains unproven in patient populations
- · Debt-to-equity of 1.40 is unusually elevated for a pre-revenue biotech and constrains financing flexibility
Catalysts
- · IRIS Phase 2 topline readout in ASD (Q3 2026) — the next binary event and potentially the swing factor for the residual thesis
- · Q2 earnings/business update on August 13, 2026 — first formal management commentary on ZEPHYR path forward and twice-daily strategy
- · Potential FDA/regulatory dialogue on ML-007C-MA path in ADP (Fast Track designation) or a twice-daily schizophrenia development plan
- · Short interest at 16.3% of float with 6.25 days-to-cover creates non-trivial squeeze potential on any positive surprise (IRIS hit, partnership, or reassuring guidance)
- · Potential partnership/licensing announcement leveraging retained global rights, particularly for ADP or ASD programs
- · Follow-on equity raise — likely dilutive but would remove near-term financing overhang if priced acceptably
Key risks
- · IRIS Phase 2 in ASD also missing — would collapse the residual optionality and likely drive the stock toward cash value
- · Emergency dilutive financing at depressed prices given ~$46.7M cash vs. $138.6M annual burn
- · Follow-through analyst downgrades from the ratings that stayed positive (TD Cowen, BMO, Jefferies) if ZEPHYR twice-daily data disappoints on deeper review
- · Cholinergic tolerability issues emerging in larger/longer patient trials, eliminating the differentiation vs. Cobenfy entirely
- · Cobenfy expanding label into ADP/ASD via BMS's Phase 3 program, foreclosing MapLight's addressable markets
- · IP challenges from Cobenfy's established patent estate around muscarinic combinations
What to watch
- · August 13, 2026 earnings — management's articulation of ZEPHYR twice-daily path and cash runway
- · IRIS ASD Phase 2 topline readout expected Q3 2026 — binary and imminent
- · Any 8-K filings announcing financing, partnership discussions, or FDA interactions
- · Short interest trends (currently 16.3% of float, 6.25 days-to-cover) heading into IRIS
- · $12.24 52-week low as key technical support; break below opens path toward cash value
- · Follow-up analyst notes from TD Cowen, BMO, Jefferies (still positive) vs. Morgan Stanley (downgraded)
Key metrics
Price target rationale
Base case ~$14 reflects modest re-rating as sell-side revises down from ~$44 toward a probability-weighted pipeline value assuming twice-daily schizophrenia path survives and IRIS is a coin-flip; bull case ~$28 assumes IRIS hits and management establishes credible twice-daily development plan, driving partial recovery toward pre-blowup levels; bear case ~$4 approximates cash-per-share territory if IRIS also misses and dilutive financing is forced.
On Wall Street's view (disagree): The $43.85 consensus target largely predates the July 27 ZEPHYR miss and Morgan Stanley/Wolfe cuts, so it materially overstates fair value until the sell-side fully re-rates. A target in the mid-teens better reflects a broken lead-asset thesis with residual IRIS optionality.
Latest filing (10-K)
MapLight is a pre-revenue CNS biotech with two Phase 2 readouts due Q3 2026 (schizophrenia and autism) that will make or break the stock, competing directly against Bristol Myers Squibb's already-approved Cobenfy with a drug designed to be better-tolerated and easier to use but unproven in patients.
MapLight Therapeutics (MPLT) is a clinical-stage CNS biopharmaceutical company with no approved products and no revenue. It discovers drug candidates by mapping neural circuits using optogenetics, single-cell transcriptomics, and spatial transcriptomics (STARmap), then develops small molecules targeting those circuits. The company went public via IPO in October 2025 and funds operations entirely through equity financing.
What the news says · bearish
MapLight Therapeutics suffered a catastrophic single-day collapse on July 27, 2026, with the stock falling somewhere between 40–73% depending on the source, after Phase 2 schizophrenia trial data came in mixed — specifically failing on the once-daily dosing arm that was considered the key commercial differentiator. Morgan Stanley downgraded the stock and Wolfe cut its price target, reflecting serious concern about the lead asset's path forward. Some bulls remain: TD Cowen, BMO, and Jefferies maintained positive ratings, and one headline noted the trial did hit a key Phase 2 goal, suggesting partial efficacy signals survived. However, the magnitude of the selloff and the analyst downgrades indicate the market views the once-daily miss as a fundamental setback to the investment thesis. A pre-trial insider sale by the CAO/Interim CFO adds a minor additional overhang.
This analysis is from Jul 28, 2026. Markets move. Get the current read on MPLT and generate fresh AI research on any ticker.
Every call we make is tracked publicly against what the stock actually did. See the track record →
One free AI report every day. No card required.